California Oncology Research Institute Inc
Public records show a registered, tax-exempt organization in good standing.
What it says it does
Mission - The California Oncology Research Institute is committed to curing cancer through educating communities, ensuring access to early detection screenings and fostering innovative research and treatments. We care about establishing relationships within Los Angeles' underserved neighborhoods to provide information about several types of cancers.
- Income
- $280,342
- Spending
- $345,019
- Spent on programs
- 93%
- Reserves
- 101.7 months of spending
- Largest source of income
- donations and private grants, 72%
- Employees
- 0
- Volunteers
- 25
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Financial health
Good: 70 out of 100. Higher than 25% of charities in its peer group (medical research, $250k to $1m).
Reserves
35 of 35Spendable reserves would cover 101.7 months of spending.
Debt
20 of 20It owes 0% of what it owns.
Living within its means
0 of 15Spending exceeded income by 23% of income.
Income trend
0 of 15Income fell 84% on the year before.
Spending floor
15 of 1593% of spending went to programs and raising each dollar of donations cost 0 cents.
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Governance
Good: 83 out of 100. Higher than 64% of charities in its peer group (medical research, $250k to $1m).
Independent board
18 of 254 of 4 voting board members are independent.
Conflict of interest policy
15 of 15Has a written conflict of interest policy.
Whistleblower policy
8 of 8Has a written whistleblower policy.
Record keeping policy
7 of 7Has a written policy on keeping and destroying records.
Board minutes
5 of 5Keeps minutes of board meetings.
Board sees the tax return
10 of 10Gave the board a copy of this return before filing it.
Independent check of accounts
6 of 15Its accounts were not audited or reviewed by an independent accountant.
No reported misuse
10 of 10Reports no diversion of assets, excess benefits or loans to insiders.
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Impact evidence
Describes programs. Its tax return describes what it does but we have found no measurable results in it.
Programs described in its return (1)
- $320,700 spent. Three Main Goals:a) Cancer Researchb) Outreach and Education c) Artificial Intelligence (AI)and d) Legacy planningExpansion of Clinical Research: The CORI doctors have the expertise, track record, and enthusiasm to continue the excellence in clinical research through federal- and industry-funded clinical trials. However, an expanded infrastructure is necessary to maintain this effort and allow for CORI to meet its outstanding potential. The expansion requires additional personnel to facilitate industry trial identification, development and negotiation of trial budgets and contracts, assistance in establishing and documenting protocols. Investment in the clinical infrastructure in the near future would allow expansion of the program. Trainees and Researchers: CORI has supported the research of leading clinicians, young researchers and educators leading to national presentations and publications in peer-review journals. All publications have and will continue to acknowledge CORI as a source of funding.Expanding Community Outreach Activities and Educational Programs: CORI intends to offer at least three cancer educational workshops and cancer screening programs to underserved communities including inner city churches throughout the greater Los Angeles area, expand the cancer screening program to include prostate and colorectal screenings, build new partnerships with other cancer awareness and/or similar cancer organizations and increase our cancer educational literature that is offered at each cancer workshop.Strategic Alliances: Given the significant financial constraints of government funded research in the areas of clinical trials, genomic sequencing and other areas of clinical and translational research, as well as to sustain the support of trainees, strong strategic partners are needed. There may be opportunities to expand existing alliances by strengthening relationships with strategic collaborators and philanthropic organizations. These include major universities in the US and Israel as well as respected foundations such as Stand up to Cancer, the American Cancer Society, Providence Health System and Cancer Support Community.Artificial Intelligence (AI) personalize cancer care (see details below)Legacy Planning: Establish legacy planning as part of its philanthropyTranslational Lab Research: Colorectal Progress Report Perform translational multi-omics on colorectal cancer (CRC) research in early onset (EOCRC) versus late onset (LOCRC) patients to better understand the cause of EOCRC and identify potential targets for treatment.Epidemiology of Early-onset colorectal cancer(EOCRC)The incidence of early-onset colorectal cancer (EOCRC), defined as diagnosis before the age of 50, is on the rise globally, in contrast to the decreasing trend in late-onset colorectal cancer (LOCRC). Since the 1990s, the incidence of EOCRC has increased by2% annually, particularly in Western countries such as North America and Western Europe. While the exact causes remain unknown, environmental demographic factors such as dietary changes, obesity, lack of physical activity, and antibiotic use are thought to play a role. EOCRC patients are also often diagnosed at advanced clinical stages (III or IV) because they are not typically targeted for routine screening, and their symptoms can be mistaken for other colon related benign conditions such as irritable bowel syndrome. The prognosis for EOCRC is poorer than for LOCRC at the same stage, due to the more aggressive biological nature of these tumors. The purpose of this study is to elucidate potential molecular pathogenic mechanisms of EOCRC which may lead to earlier diagnosis and potential targets for therapy.
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Legitimacy checks
Is it registered with the IRS? Passed.
Listed in the IRS master file of tax-exempt organizations as a 501(c)(3) charitable organization.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
Has the IRS revoked its tax-exempt status? Passed.
Not on the IRS automatic revocation list.
Source: Automatic revocation of exemption list, Internal Revenue Service, file dated November 6, 2026.
Are donations tax-deductible? Passed.
On the IRS list of organizations eligible to receive tax-deductible contributions.
Source: Publication 78 data: organizations eligible for tax-deductible contributions, Internal Revenue Service, file dated October 13, 2026.
Is it keeping up with its IRS filings? Passed.
Most recent return on file covers the year ending December 2024.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
How long has it been tax-exempt? Passed.
Recognized by the IRS since February 2009.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
Is it in good standing with state regulators? Passed.
Not on California's list of charities barred from soliciting. Other states are not yet checked.
Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated November 4, 2026.
Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.